Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
DXCM heads into its October 29 earnings date with an unusual split: analyst conviction has rarely looked stronger, yet short interest has been grinding higher for six weeks and the stock is down 5% on the month.
The Street's direction is emphatically constructive. Barclays initiated with an Overweight rating and a $115 target this week, the most bullish call on the name in recent months. RBC Capital raised its target to $105 from $90 just days earlier. Truist, TD Cowen, and several others have also lifted numbers since the strong Q2 print in late July, when the stock jumped 11% on the day and held most of that gain through the week. The consensus sits at Buy, with a mean price target of $96.23 against a current price of $83.39, implying roughly 15% upside from here. Bulls point to the CONNECT trial data showing a 1.6% A1c reduction in T2 non-intensive insulin patients, expanding CMS coverage, and 2026 revenue guidance of $5.16B to $5.25B with adjusted gross margins of 63 to 64%. Bears counter that CGM competitive pressure is intensifying, payor pricing creates a ceiling on margin expansion, and the stock's premium multiple leaves little room for execution missteps.
Positioning in the lending market does nothing to contradict the bullish analyst tone. The borrow market for DXCM remains extremely loose, with availability running at roughly 3,335% of short interest. That means there are more than 33 times as many shares available to lend as there are currently borrowed, one of the least constrained borrow markets in the sector. Cost to borrow is a negligible 0.47%, barely above the general collateral rate. Nothing in the lending data suggests a short campaign of any real conviction.
Yet short interest itself has been drifting higher. At 4.4% of the free float, it is not extreme, but the 30-day increase of 7.4% is worth noting. Shorts added modestly through September, with a small jump on the first trading days of October. The ORTEX short score of 38.9 sits in the lower half of its historical range, so overall the model does not flag this as a high-conviction short setup. The week-on-week short interest rise of 0.55% looks more like cautious hedging ahead of earnings than a directional bet. Options markets are similarly relaxed: the put/call ratio of 0.71 is actually below its 20-day average of 0.75, meaning call volumes are running slightly ahead of puts. That is not a defensive posture.
One angle worth tracking in the institutional register is the Vanguard reorganisation. The original Vanguard Group entity filed a 13G/A in March 2026 showing its position falling to zero from 12.6%, while two successor Vanguard entities (Vanguard Capital Management and Vanguard Portfolio Management) filed fresh 13G schedules in April 2026 showing combined holdings of roughly 12.5% of the class. As with all Schedule 13D/G disclosures, these are event-driven around the 5% threshold and reflect positions as last disclosed. Separately, insider activity over the past 90 days shows net selling of around 107,000 shares with a net value of approximately $8.7M, but every transaction in the recent file carries a 10b5-1 plan designation. Planned sales under pre-arranged trading programmes carry far less signal than discretionary ones.
Retail attention to DXCM has also faded, with Wikipedia page views running about 1.8 standard deviations below the stock's own 90-day average. That measures attention, not revenue, but it does suggest the name is not attracting fresh speculative interest in the near term. Close peer PODD gained 1.4% on the week while DXCM fell 3.75%. IDXX dropped 3.4%, suggesting at least some of the DXCM weakness is sector-level rather than name-specific.
The October 29 earnings date is the single most important event on the horizon: the last comparable print produced an 11% one-day move, and the setup this time is a stock that has given back ground while the Street has raised numbers. Whether that gap between analyst target lifts and the share price decline closes on the report or widens is the question worth watching over the next three weeks.
See the live data behind this article on ORTEX.
Open DXCM on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
